ESMO 2019

Postsurgery Observation Better Than Radiotherapy in Men with Prostate Cancer

Phoebe Starr

December 2019, Vol 10, No 6 - ESMO 2019

Barcelona, Spain—Results of the new clinical trial RADICALS-RT indicate that using salvage radiotherapy immediately after surgery leads to equivalent outcomes in terms of progression-free survival (PFS) versus adjuvant radiotherapy in men with prostate cancer undergoing radical prostatectomy. These late-breaking results were presented at the ESMO Congress 2019 by lead investigator Chris Parker, MD, FRCR, MRCP, Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, England. [ Read More ]

Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations

Phoebe Starr

December 2019, Vol 10, No 6 - ESMO 2019

Barcelona, Spain—The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza) delayed disease progression and showed a trend toward improved survival compared with newer hormonal agents in men with pretreated metastatic castrate-resistant prostate cancer (CRPC) and homologous recombinant repair (HRR) gene mutations or with BRCA1, BRCA2, and ATM mutations. Results of this late-breaker were reported at the ESMO Congress 2019 during the presidential session. [ Read More ]

Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer

Phoebe Starr

December 2019, Vol 10, No 6 - ESMO 2019

Barcelona, Spain—Poly (ADP-ribose) polymerase (PARP) inhibition has an established role as maintenance therapy in women with newly diagnosed high-grade advanced ovarian cancer and a BRCA mutation. At the ESMO Congress 2019, results of 3 clinical trials expand the use of PARP inhibition in ovarian cancer to all patients. The 3 studies had different enrollment criteria, used a different PARP inhibitor, and 2 of them used PARP inhibitor plus bevacizumab (Avastin); however, taken together, all 3 trials show that the PARP inhibition era is here. [ Read More ]

Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care

Phoebe Starr

October 2019, Vol 10, No 5 - ESMO 2019

Barcelona, Spain—Late-breaking data from 2 clinical trials presented at ESMO 2019 will likely change the treatment paradigm for pre- or postmenopausal women with hormone receptor (HR)-­positive, HER2-negative breast cancer, regardless of menopausal status. The MONALEESA-3 study and the MONARCH-2 study showed an improved overall survival (OS) with the addition of the CDK4/6 inhibitor ribociclib (Kisqali) or abemaciclib (Verzenio) to endocrine therapy as first- or second-line therapy. The results were presented at the Presidential Session of the meeting. [ Read More ]